{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:03:03Z","timestamp":1769234583517,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL126724"],"award-info":[{"award-number":["R01HL126724"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL126850"],"award-info":[{"award-number":["R01HL126850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL144552"],"award-info":[{"award-number":["R01HL144552"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL157975"],"award-info":[{"award-number":["R01HL157975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jtha.2023.04.012","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:17:21Z","timestamp":1681820241000},"page":"2101-2113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice"],"prefix":"10.1016","volume":"21","author":[{"given":"Giang N.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Seleme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samita","family":"Kafle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine B.","family":"Zander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. Long","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise E.","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.04.012_bib1","first-page":"342","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"NatMed"},{"key":"10.1016\/j.jtha.2023.04.012_bib2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.04.012_bib3","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","article-title":"Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV","volume":"28","author":"Morales","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.04.012_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2023.04.012_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.13543","article-title":"Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A","volume":"15","author":"Nguyen","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.04.012_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1432-1033.1995.tb20776.x","article-title":"Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization","volume":"232","author":"Lind","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jtha.2023.04.012_bib7","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2009-05-220327","article-title":"Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model","volume":"114","author":"Sabatino","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib8","doi-asserted-by":"crossref","first-page":"21643","DOI":"10.1074\/jbc.M402107200","article-title":"Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized","volume":"279","author":"Toso","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.04.012_bib9","doi-asserted-by":"crossref","first-page":"23652","DOI":"10.1016\/S0021-9258(18)35888-5","article-title":"Coagulant properties of hybrid human\/porcine factor VIII molecules","volume":"267","author":"Lollar","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.04.012_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in\u00a0vitro","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2023.04.012_bib12","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1182\/blood.V88.9.3446.bloodjournal8893446","article-title":"Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies","volume":"88","author":"Bi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib13","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood-2003-05-1519","article-title":"Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment","volume":"102","author":"Yarovoi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omtm.2021.11.005","article-title":"Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A","volume":"24","author":"Elkouby","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.04.012_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.gt.3300680","article-title":"Adeno-associated virus vectors can be efficiently produced without helper virus","volume":"5","author":"Matsushita","year":"1998","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2023.04.012_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2015-03-634329","article-title":"Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity","volume":"126","author":"Ivanciu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib17","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1002\/cpmo.61","article-title":"Assessing blood clotting and coagulation factors in mice","volume":"9","author":"Brake","year":"2019","journal-title":"Curr Protoc Mouse Biol"},{"key":"10.1016\/j.jtha.2023.04.012_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1172\/JCI108788","article-title":"Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand\u2019s disease","volume":"60","author":"Weiss","year":"1977","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.04.012_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1042\/bj2570679","article-title":"The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII","volume":"257","author":"Leyte","year":"1989","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2023.04.012_bib20","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1016\/S0021-9258(19)81537-5","article-title":"Association of the factor VIII light chain with von Willebrand factor","volume":"263","author":"Lollar","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.04.012_bib21","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1016\/S0021-9258(18)60704-5","article-title":"An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor","volume":"263","author":"Foster","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.04.012_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib23","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.04.012_bib24","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.04.012_bib25","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.94.22.11851","article-title":"Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa","volume":"94","author":"Pipe","year":"1997","journal-title":"Proc Nat Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.04.012_bib26","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.04.012_bib28","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib29","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.2020007562","article-title":"Activated protein C has a\u00a0regulatory role in factor VIII function","volume":"137","author":"Wilhelm","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for haemophilia a using a novel human factor VIII variant","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.04.012_bib31","doi-asserted-by":"crossref","first-page":"38345","DOI":"10.1074\/jbc.M206959200","article-title":"High level expression of recombinant porcine coagulation factor VIII","volume":"277","author":"Doering","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.04.012_bib32","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623003306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623003306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:38Z","timestamp":1761536258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1538783623003306"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.04.012","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}